# The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults

> **NCT06027554** · PHASE2 · RECRUITING · sponsor: **UConn Health** · enrollment: 60 (estimated)

## Conditions studied

- Frailty
- Mild Cognitive Impairment
- Aging

## Interventions

- **DRUG:** Mitoquinone Mesylate
- **DIETARY_SUPPLEMENT:** Placebo capsule

## Key facts

- **NCT ID:** NCT06027554
- **Lead sponsor:** UConn Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-07
- **Primary completion:** 2027-03-01
- **Final completion:** 2028-02-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-01-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06027554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06027554, "The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06027554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*